Absci, a company specialising in generative AI drug creation, and PrecisionLife, a leader in computational biology for complex chronic diseases, have unveiled a robust partnership aimed at developing a collaborative portfolio of potential therapeutics. The primary objective of this collaboration is to capitalise on the unique strengths of both entities to address unmet medical needs and expedite the drug development process.
The key elements of this partnership include the joint creation of a pipeline wherein Absci and PrecisionLife will collaborate on the discovery and development of biotherapeutics for up to five mutually agreed-upon targets and indications. Both companies will actively engage in target selection, program development, and potentially participate in future commercialisation efforts, fostering a shared success model. PrecisionLife's expertise in understanding complex diseases will complement Absci's AI capabilities, enabling the pinpointing of the most promising targets for effective therapeutic development.
This strategic collaboration has yielded significant results for Absci, as evidenced by the acquisition of ten new Active Programs in 2023, surpassing the company's annual target. This achievement underscores the increasing traction and value proposition of Absci's AI-powered drug creation platform.
Sean McClain, Founder & CEO of Absci, expressed enthusiasm about the collaboration, stating, "This collaboration combines our complementary strengths to create a high-value pipeline of novel therapeutics. PrecisionLife’s disease biology insights complement our AI, accelerating the development of potentially effective treatments for patients in need."
Click here to read the original news story.